Graft glycocalyx degradation in human liver transplantation

PLoS One. 2019 Aug 15;14(8):e0221010. doi: 10.1371/journal.pone.0221010. eCollection 2019.

Abstract

Objective: Ischaemia/reperfusion-injury degrades endothelial glycocalyx. Graft glycocalyx degradation was studied in human liver transplantation.

Methods: To assess changes within the graft, blood was drawn from portal and hepatic veins in addition to systemic samples in 10 patients. Plasma syndecan-1, heparan sulfate and chondroitin sulfate, were measured with enzyme-linked immunosorbent assay.

Results: During reperfusion, syndecan-1 levels were higher in graft caval effluent [3118 (934-6141) ng/ml, P = 0.005] than in portal venous blood [101 (75-121) ng/ml], indicating syndecan-1 release from the graft. Concomitantly, heparan sulfate levels were lower in graft caval effluent [96 (32-129) ng/ml, P = 0.037] than in portal venous blood [112 (98-128) ng/ml], indicating heparan sulfate uptake within the graft. Chondroitin sulfate levels were equal in portal and hepatic venous blood. After reperfusion arterial syndecan-1 levels increased 17-fold (P < 0.001) and heparan sulfate decreased to a third (P < 0.001) towards the end of surgery.

Conclusion: Syndecan-1 washout from the liver indicates extensive glycocalyx degradation within the graft during reperfusion. Surprisingly, heparan sulfate was taken up by the graft during reperfusion. Corroborating previous experimental reports, this suggests that endogenous heparan sulfate might be utilized within the graft in the repair of damaged glycocalyx.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Glycocalyx / metabolism*
  • Glycocalyx / pathology
  • Heparitin Sulfate / metabolism*
  • Humans
  • Liver / metabolism*
  • Liver / pathology
  • Liver Transplantation*
  • Middle Aged
  • Reperfusion Injury / metabolism*
  • Reperfusion Injury / pathology
  • Syndecan-1 / metabolism*

Substances

  • SDC1 protein, human
  • Syndecan-1
  • Heparitin Sulfate

Associated data

  • figshare/10.6084/m9.figshare.8111201
  • figshare/10.6084/m9.figshare.8874572

Grants and funding

This work was supported by Helsinki University Central Hospital EVO Grants TYH2015123 and TYH2014116 to EP. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.